REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$9.72 USD
+0.37 (3.96%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $9.73 +0.01 (0.10%) 7:14 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for REGENXBIO Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 275 | 365 | 457 | 476 | 296 |
Receivables | 25 | 28 | 32 | 43 | 38 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 35 | 23 | 29 | 12 | 11 |
Total Current Assets | 335 | 416 | 519 | 531 | 345 |
Net Property & Equipment | 132 | 142 | 132 | 56 | 29 |
Investments & Advances | 39 | 201 | 392 | 47 | 104 |
Other Non-Current Assets | 1 | 2 | 2 | 3 | 4 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 8 | 8 | 7 | 6 |
Total Assets | 574 | 833 | 1,114 | 708 | 498 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 27 | 11 | 11 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 50 | 47 | 76 | 49 | 25 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 51 | 50 | 41 | 19 | 0 |
Total Current Liabilities | 130 | 130 | 130 | 81 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 4 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 50 | 98 | 134 | 175 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 262 | 317 | 350 | 330 | 48 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,021 | 973 | 928 | 667 | 628 |
Retained Earnings | -705 | -442 | -161 | -289 | -178 |
Other Equity | -4 | -15 | -3 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 312 | 516 | 764 | 378 | 450 |
Total Liabilities & Shareholder's Equity | 574 | 833 | 1,114 | 708 | 498 |
Total Common Equity | 312 | 516 | 764 | 378 | 450 |
Shares Outstanding | 43.90 | 43.20 | 42.70 | 37.40 | 36.80 |
Book Value Per Share | 7.10 | 11.95 | 17.90 | 10.10 | 12.23 |
Fiscal Year End for REGENXBIO Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 290 | 339 | 275 | 302 | 320 |
Receivables | 23 | 16 | 25 | 28 | 21 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 34 | 41 | 35 | 36 | 37 |
Total Current Assets | 347 | 395 | 335 | 366 | 379 |
Net Property & Equipment | 124 | 128 | 132 | 136 | 139 |
Investments & Advances | 37 | 42 | 39 | 63 | 95 |
Other Non-Current Assets | 0 | 1 | 1 | 1 | 1 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 6 | 7 | 7 | 6 |
Total Assets | 569 | 629 | 574 | 634 | 682 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 16 | 31 | 23 | 22 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 42 | 33 | 50 | 46 | 51 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 32 | 39 | 51 | 53 | 49 |
Total Current Liabilities | 98 | 110 | 130 | 127 | 118 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 45 | 50 | 59 | 73 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 221 | 239 | 262 | 271 | 277 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,172 | 1,162 | 1,021 | 1,013 | 996 |
Retained Earnings | -821 | -768 | -705 | -642 | -580 |
Other Equity | -2 | -3 | -4 | -7 | -10 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 348 | 391 | 312 | 363 | 406 |
Total Liabilities & Shareholder's Equity | 569 | 629 | 574 | 634 | 682 |
Total Common Equity | 348 | 391 | 312 | 363 | 406 |
Shares Outstanding | 49.40 | 49.00 | 43.90 | 43.90 | 43.90 |
Book Value Per Share | 7.05 | 7.97 | 7.10 | 8.27 | 9.25 |